1.27  -0.03 (-2.31%)		10-09 16:00
Open: 1.33 High: 1.34 Volume: 82,144		Pre. Close: 1.3 Low: 1.27 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :	2.23	1-year :	2.69
Resists	First :	1.91	Second :	2.3
Pivot price	1.61
Supports	First :	1.26	Second :	1.05
MAs	MA(5) :	1.41	MA(20) :	1.7
	MA(100) :	3.25	MA(250) :	8.66
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	2.2	D(3) :	4.2
RSI	RSI(14): 20.7
52-week	High :	36	Low :	1.26

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CALC ] has closed above bottom band by 0.1%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.35 - 1.36	1.36 - 1.37
Low:	1.24 - 1.26	1.26 - 1.27
Close:	1.25 - 1.28	1.28 - 1.29

CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.

Mon, 05 Oct 2026
20,000 director stock options carry a $1.64 exercise price at CalciMedica (CALC). - Stock Titan

Thu, 01 Oct 2026
CalciMedica Establishes $25 Million ATM Stock Program - The Globe and Mail

Wed, 30 Sep 2026
Stock sales may occur from time to time for CalciMedica (CALC) through H.C. Wainwright. - Stock Titan

Mon, 28 Sep 2026
CalciMedica CEO Rachel A. Leheny Awarded 360,000 Stock Options with Four-Year Vesting - Kalkine Media

Mon, 07 Sep 2026
CalciMedica, Inc. (CALC) Stock Price & News - Syfe

Thu, 27 Aug 2026
CalciMedica Announces One-for-Five Reverse Stock Split - The Manila Times

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	7 (M)
Shares Float	4 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	65 (K)
Shares Short P.Month	192 (K)

EPS	-6.85
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.89
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-63.6 %
Return on Equity (ttm)	-365.8 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.87
Qtrly Earnings Growth	0 %
Operating Cash Flow	-19 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-0.19
PEG Ratio	0
Price to Book value	1.41
Price to Sales	0
Price to Cash Flow	-0.46

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.